Mobilisation of peripheral blood progenitor cells (PBPCs)

Indication for Lenograstim

Population group: Suitable for both men and women, only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Lenograstim is indicated in adults, adolescents and children aged older than 2 years for the mobilisation of peripheral blood progenitor cells (PBPCs), for patients as well as healthy donors.

For this indication, competent medicine agencies globally authorize below treatments:

150 μg/m² once daily

Route of admnistration

Subcutaneous

Defined daily dose

150 - 150 ug per m² of body surface area (BSA)

Dosage regimen

From 150 To 150 ug per m² of body surface area (BSA) once every day

Detailed description

After chemotherapy, lenograstim should be administered daily, at the recommended dose of 19.2 MIU (150 µg) per m² per day as a subcutaneous injection starting within 1 to 5 days after completion of chemotherapy, according to the chemotherapy regimen administered for mobilisation.

Lenograstim should be maintained until the last leukapheresis.

Leukapheresis should be performed when the post nadir leukocyte count is rising or after assessment of CD34+ cells in blood with a validated method. For patients who have not had extensive chemotherapy, one leukapheresis is often sufficient to obtain the acceptable minimum yield (≥2.0 × 106 CD34+ cells per kg).

In PBPC mobilisation with lenograstim alone, lenograstim should be administered daily at the recommended dose of 1.28 MIU (10 µg) per kg per day as a subcutaneous injection for 4 to 6 days. Leukapheresis should be performed between day 5 and 7.

In patients who have not had extensive chemotherapy one leukapheresis is often sufficient to obtain the acceptable minimum yield (≥2.0 × 106 CD34+ cells per kg).

In healthy donors, a 10µg/kg daily dose administered subcutaneously for 5-6 days allows a CD34+ cells collection ≥3 × 106/kg body weight with a single leukapheresis in 83% of subjects and with 2 leukapheresis in 97%.

19.2 MIU/m² once daily

Route of admnistration

Subcutaneous

Defined daily dose

19,200,000 - 19,200,000 [iU] per m² of body surface area (BSA)

Dosage regimen

From 19,200,000 To 19,200,000 [iU] per m² of body surface area (BSA) once every day

Detailed description

After chemotherapy, lenograstim should be administered daily, at the recommended dose of 19.2 MIU (150 µg) per m² per day as a subcutaneous injection starting within 1 to 5 days after completion of chemotherapy, according to the chemotherapy regimen administered for mobilisation.

Lenograstim should be maintained until the last leukapheresis.

Leukapheresis should be performed when the post nadir leukocyte count is rising or after assessment of CD34+ cells in blood with a validated method. For patients who have not had extensive chemotherapy, one leukapheresis is often sufficient to obtain the acceptable minimum yield (≥2.0 × 106 CD34+ cells per kg).

In PBPC mobilisation with lenograstim alone, lenograstim should be administered daily at the recommended dose of 1.28 MIU (10 µg) per kg per day as a subcutaneous injection for 4 to 6 days. Leukapheresis should be performed between day 5 and 7.

In patients who have not had extensive chemotherapy one leukapheresis is often sufficient to obtain the acceptable minimum yield (≥2.0 × 106 CD34+ cells per kg).

In healthy donors, a 10µg/kg daily dose administered subcutaneously for 5-6 days allows a CD34+ cells collection ≥3 × 106/kg body weight with a single leukapheresis in 83% of subjects and with 2 leukapheresis in 97%.

Active ingredient

Lenograstim belongs to the cytokine group of biologically active proteins which regulate cell differentiation and cell growth. Lenograstim induces a marked increase in peripheral blood neutrophil counts within 24 hours of administration.

Read more about Lenograstim

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner